Wilms tumor is an embryonal tumor of the kidney thought to derive from mesenchymal precursor cells. Approximately 1 ± 2% of Wilms tumors are familial (Breslow et al., 1993) . The etiology of Wilms tumorigenesis is known to be complex, with four or more loci (WT1 at 11p13, FWT1 at 17q12-21, FWT2 at 19q13.4, and additional WT genes at 11p15, 1p, 7p, and/or 16q) implicated in the development of WT (Call et al., 1990; Gessler et al., 1990; Rahman et al., 1996; Hu et al., 1997; McDonald et al., 1998; Mannens et al., 1990; Maw et al., 1992; Miozzo et al., 1996) . Thus far, WT1 at 11p13 is the only WT gene to be identi®ed and characterized. WT1 has been excluded as the WT predisposition gene in most families studied, but a gene at 19q13.4 (FWT2) has been linked to WT predisposition in ®ve WT families (McDonald et al., 1998) .
The PPP2R1A gene, encoding the a isoform of the 65kd structural/regulatory subunit A of the serine/ threonine protein phosphatase 2A (PP2A) holoenzyme, is located within the FWT2 candidate region at 19q13.4. PP2A is an apparently ubiquitous enzyme involved in DNA replication, cell proliferation, and cell fate determination (Mumby and Walter, 1993; MayerJaekel and Hemmings, 1994; Depaoli-Roach et al., 1994; Lin et al., 1998; reviewed in Virshup, 2000) and is important for the normal growth and dierentiation of the metanephric kidney in rats (Svennilson et al., 1995) . The expression of all three subunits of this heterotrimeric enzyme are regulated in a cell-speci®c and developmental stage-speci®c manner in rat kidney, with the highest levels of enzyme activity present in the nephrogenic cortex (particularly the S-shaped bodies) of fetal kidney (Everett et al., 1999) . Interestingly, this pattern of expression is similar to that of the Wilms tumor suppressor gene WT1 (Pritchard-Jones et al., 1990; Grubb et al., 1994) .
PP2A plays a role in the Wnt signaling pathway and has been shown to be present in the multiprotein complex containing the adenomatous polyposis coli (APC) protein, the serine/threonine kinase GSK3b, and axin (Fagotto et al., 1999; Hsu et al., 1999; Seeling et al., 1999; Ikeda et al., 2000) , suggesting that PP2A has a role in regulating the activity of this complex. Overexpression of the PP2A B56 regulatory subunit has been shown to markedly reduce b-catenin levels in mammalian cells (Seeling et al., 1999) , which suggests that increased levels of PP2A accelerate the phosphorylation-dependent proteolysis of b-catenin. Interestingly, b-catenin mutations have recently been reported to occur in about 15% of Wilms tumors (Koesters et al., 1999; Maiti et al., 2000) , suggesting that the APC/ b-catenin/Tcf-Lef pathway is involved in Wilms tumorigenesis. Since PP2A also plays a role in the Wnt signaling pathway, alterations in one or more of the PP2A subunits could plausibly aect this pathway and contribute to Wilms tumorigenesis.
Multiple lines of evidence suggest that some protein phosphatases act as tumor suppressors. Alterations in the b isoform of the structural/regulatory subunit A of PP2A (PPP2R1B, located at 11q22-24), which has 86% identity with the PPP2R1A gene (Hendrix et al., 1993) , have been implicated in the etiology of human lung and colon cancers (Wang et al., 1998) and breast cancers (Calin et al., 2000) suggesting that PPP2R1B is a tumor suppressor gene. The PPP2R1A gene itself has very recently been shown to be altered in a small percentage (4 ± 5%) of primary breast and lung carcinomas and in a melanoma cell line (Calin et al., 2000) . Another protein phosphatase, the PTEN/ MMAC1/TEP1 gene, has been shown to be a tumor suppressor whose inactivation is observed in a variety of human cancers including glioma, prostate cancer, melanoma, endometrial cancer, and lung cancer Li and Sun, 1997; Steck et al., 1997) . A fourth protein phosphatase gene, the PPP1R3 gene encoding the regulatory subunit 3 of PP1, has recently been shown to be mutated in primary lung cancers and cell lines from lung, ovarian, colorectal, and gastric cancers (Kohno et al., 1999; Takakura et al., 2000) . The protein phosphatase inhibitor okadaic acid, which at low levels is speci®c for PP2A (Bialojan and Takai, 1988 ) is a tumorigenic agent (Suganuma et al., 1988; Afshari et al., 1993) . Finally, the regulatory (PP2A-A) and catalytic (PP2A-C) subunits of PP2A associate with the polyoma virus small and middle tumor (T) antigens and SV40 small tumor (t) antigen to form complexes in which the DNA tumor virus antigens replace the B subunit of PP2A and modulate its substrate speci®city, strongly suggesting that the cellular PP2A heterotrimer acts as a tumor suppressor (Pallas et al., 1990; Walter et al., 1990) . From these studies and the speculation that protein phosphatases suppress tumor formation by antagonizing oncogenic protein kinases, it seems likely that a number of protein phosphatase genes will be shown to function as tumor suppressors.
The expression of PP2A in fetal kidney, its role in kidney development, the evidence that multiple protein phosphatases may act as tumor suppressors, and the location of PPP2R1A within the FWT2 region at 19q13.4 combined to point to the PPP2R1A gene as a compelling candidate for the FWT2 gene. In this study we examined the PPP2R1A gene for alterations in blood and tumor RNA and DNA from 34 Wilms tumor patients, including aected members of four of the ®ve Wilms tumor families demonstrating linkage to the FWT2 gene on chromosome 19q13.4 (McDonald et al., 1998) and 30 sporadic Wilms tumor patients.
A total of 32 RNA samples isolated from primary Wilms tumors (see Table 1 ) were assessed for alterations in the PPP2R1A coding region by RT ± PCR and sequence analysis. Two of these RNA samples were isolated from tumors (F1-T and F4-T) from 19q-linked familial Wilms tumor patients, and 30 RNA samples were from sporadic Wilms tumors (T1-T30). Figure 1 depicts the PPP2R1A mRNA and the primers used to amplify and sequence the entire coding region of the gene. Except for silent, heterozygous, single-base changes in six of the 32 RNA samples (four of the six showing the same silent alteration in exon 14), no alterations were observed in the PPP2R1A coding region in any of these 32 tumor RNAs. We observed a CG dinucleotide at nt 910 ± 911 (with reference to the PPP2R1A cDNA sequence, accession #NM_014225) in all samples sequenced. This dinucleotide is indicated as GC in the published sequence of PPP2R1A and apparently indicates an error in the published sequence.
In order to design intronic primers for the ampli®ca-tion of all exons of PPP2R1A from genomic DNA, we derived the intron ± exon structure of the PPP2R1A gene by comparing the cDNA sequence with the working draft genomic sequence (accession #AC010320), collected from a human BAC clone (CTD-2525I3; BC764800) mapped to *57 Mb on the metric physical map of chromosome 19 (Ashworth et al., 1995) . Our homology search revealed that the gene consists of 15 exons, spanning a region 36 kb in length (Figures 1 and 2) . Interestingly, although the PP2A-Aa protein consists of 15 tandemly repeated HEAT (huntingtin-elongation factor-PP2A subunit A-TOR kinase) motifs (Walter et al., 1989; Hemmings et al., 1990) , the individual HEAT motifs do not correspond to separate PPP2R1A exons (Figure 1) .
We analysed DNA samples from aected members of the three largest FWT families linked to 19q13.4 c   T2  N  T3  C1860T, ex14, het, D574D  T4  N  T5  N  T6  N  T7  N  T8  N  T9  N  T10  N  T11 C1860T, ex14, het, D574D  T12  N  T13  N  T14  N  T15  N  T16  N  T17  N  T18  N  T19  N  T20  N  T21  N  T22 C615T, ex4, het, S159S b   T23  N  T24  N  T25  N  T26  N  T27  C1860T, ex14, het, D574D  T28  N  T29  N  T30  N   a   heterozygous,   b allele frequency 1/68 (1.5%), c allele frequency 4/68 (6%) (McDonald et al., 1998) for alterations in all 15 exons of PPP2R1A. One of these DNA samples was from the F1-T tumor mentioned above, and the others were isolated from peripheral blood samples (F2-B and F3-B; see Table 1 ). Six genomic PCR products (see Figure  2) , encompassing every exon of PPP2R1A, were generated using intronic primers and then sequenced. Other than the silent heterozygous exon 6 alteration in F1-T seen in the RT ± PCR analysis and a silent heterozygous exon 9 alteration in F2-B (see Table 1 ), no changes were observed in any of the 15 exons of PPP2R1A in any of the three familial DNA samples.
Since large heterozygous deletions or insertions in the PPP2R1A gene might go undetected by RT ± PCR or genomic DNA sequence analysis, we examined a panel of DNA samples from 117 sporadic Wilms tumors, eight familial Wilms tumors, and 13 normal tissues from aected members of WT families (including both families linked and unlinked to FWT2) by Southern blot analysis with a PPP2R1A cDNA probe. This panel included 27 of the 30 sporadic tumor DNA samples and all four of the familial samples used for our mutational analysis of PPP2R1A. A common restriction fragment length polymorphism was observed, but no indication of alterations in the PPP2R1A gene was seen in any of the 138 Wilms tumor and FWT family DNA samples in our panel (data not shown).
Previous work in our laboratory has provided compelling evidence for a familial WT gene at 19q, implicated in the predisposition to Wilms tumor in a subset of WT families. Five WT families show evidence for linkage to a predisposition gene at 19q13.4, and aected members of two unlinked families demonstrate loss of heterozygosity (LOH) in this region (McDonald et al., 1998) . In addition, 10% (15/148, including two of the 30 tumors analysed in this study) of sporadic Wilms tumors analysed in our laboratory show LOH Figure 1 RT ± PCR and sequencing of the PPP2R1A mRNA. The 15 tandemly repeated HEAT motifs (see text) present in the PPP2R1A mRNA are indicated by horizontal lines; below is represented the structure of the 15 PPP2R1A exons. The translation start codon is indicated by an arrow, and the translation termination codon by UGA. The connected arrowheads indicate the primers used for RT ± PCR and the 1897 bp product generated from these primers. The ®lled and open arrows correspond, respectively, to the forward and reverse primers used to sequence the RT ± PCR product (see Table 2 ). Following informed consent, resected tumor samples were obtained from two familial and 30 sporadic Wilms tumor patients (Table 1) . RNA was extracted from tissues as previously described (Miwa et al., 1992) . For RT ± PCR, 500 ng of total RNA from 32 primary Wilms tumors was used to generate PPP2R1A cDNA using the Titan One Tube RT ± PCR System (Roche Molecular Biochemicals). Reverse transcription was done using primer 1997R (see Table 2 ) followed by PCR ampli®cation using primers 101F and 1997R. PCR ampli®cation (10 cycles of 948 30 s, 618C 30 s, 688C 2 m in followed by 25 cycles of 948C 30 s, 618C 30 s, 688C 2 m+5 s added per cycle) generated a product of 1897 bp, which spans the entire coding region of PPP2R1A. This RT ± PCR product was then reampli®ed (30 cycles of 948C 15 s, 618C 30 s, 688C 2 m) in order to generate sucient product for sequence analysis. Four internal primers (382F, 461R, 905F and 1391F) were used for sequencing. Sequencing was performed using the automated ABI PRISM dGTP BigDye terminator reaction system (Applied Biosystems, Model 377) Figure 2 Genomic PCR and sequencing of the PPP2R1A gene. The six genomic PCR products generated for the purposes of sequencing all 15 exons of PPP2R1A are indicated by connected arrowheads. Filled and open arrows indicate, respectively, forward and reverse primers used only for sequencing (see Table 2 ). DNA was isolated as previously described (Hu et al., 1990 ) from peripheral blood samples (obtained following informed consent) from two familial Wilms tumor patients, as well as from one of the familial Wilms tumor patient samples described in the legend to Figure 1 . One hundred nanograms of each DNA sample was used to generate PCR products spanning all 15 exons of the PPP2R1A gene. The PPP2R1A genomic primer pairs and PCR conditions were as shown in Table 2 at multiple markers on 19q (unpublished observation), which is signi®cant since Wilms tumors show a very low level (55%) of LOH genome-wide (Maw et al., 1992) .
For the reasons discussed above, the PPP2R1A gene encoding the a isoform of the structural/regulatory subunit of PP2A was a very attractive candidate for the FWT2 gene at 19q13.4. Multiple lines of evidence indicate that this gene, the PPP2R1B gene encoding the b isoform of the PP2A subunit A, and other serine/ threonine protein phosphatase genes act as tumor suppressors. Studies demonstrating an important role for PP2A in kidney development, and the observation that PP2A is expressed in the same cells and at the same stage of development as WT1, further suggested that alterations of PPP2R1A might play a part in the etiology of Wilms tumor.
Our thorough sequence analysis of the coding region of PPP2R1A in a total of 32 RNA samples from sporadic and 19q-linked familial Wilms tumors and three DNA samples from tumor and normal tissue from aected members of three linked WT families has revealed no mutations of PPP2R1A in any of the samples examined. Our observation of four distinct heterozygous silent single-base alterations, likely to represent polymorphisms, in the PPP2R1A coding region demonstrates that we would have readily identi®ed heterozygous single-base mutations in the gene. None of these silent alterations appears to aect the splicing of the PPP2R1A RNA, since only a single major product was observed following RT ± PCR ampli®cation of the PPP2R1A coding region from each of the 32 RNAs. The ampli®cation of roughly equal levels of product (data not shown) from RT ± PCR of each of these RNAs suggests that the PPP2R1A transcript is represented in each RNA at approximately equal levels and therefore that mutations altering the activity of the PPP2R1A promoter are unlikely to be present in these Wilms tumors. Our Southern blot analysis of 138 DNAs from sporadic and familial Wilms tumors and normal tissues from aected members of WT families demonstrated no visible deletions, insertions, or rearrangements in the PPP2R1A gene in any of this large panel of DNAs. We conclude then that mutation of PPP2R1A is not a common event in the development of Wilms tumor, although our study of 32 tumors cannot rule out a low incidence (5 ± 10%) of PPP2R1A mutations in Wilms tumor. We further conclude that alterations within the coding region of PPP2R1A are not responsible for predisposition to Wilms tumor in four WT families linked to 19q13.4 or involved in tumorigenesis in any of the 30 sporadic tumors tested, and therefore that PPP2R1A is unlikely to be the FWT2 gene located at 19q13.4.
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